Physician profile
Jasmeet Gill
NPI 1356554356
$7,523.48
in general payments reported to CMS, 2019-2025
29 companies · $2,740 in 2025
The $2,740 reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,005 · 2020: $531 · 2021: $763 · 2022: $458 · 2023: $828 · 2024: $1,200 · 2025: $2,740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,767.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,163.16 | 2024-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $1,054.25 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Cranial Technologies, INC | $985.49 | 2019-2025 | Doc Band |
| Glaxosmithkline, LLC. | $758.47 | 2019-2025 | Bexsero, Nucala |
| Phadia US INC. | $557.25 | 2019-2025 | Immunocap |
| Pfizer INC. | $476.81 | 2019-2025 | |
| Alk-Abello, INC | $327.15 | 2024-2025 | Neffy, Grastek, Odactra |
| Sanofi Pasteur INC. | $325.68 | 2019-2025 | |
| Genzyme Corporation | $313.90 | 2024-2025 | |
| Kaleo, INC. | $210.13 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $195.82 | 2025 | Neffy |
| Organon LLC | $181.05 | 2025 | Vtama |
| Kowa Pharmaceuticals America, INC. | $144.42 | 2025 | Zoryve |
| Kyowa Kirin, INC. | $121.83 | 2025 | |
| Hoffmann-La Roche Limited | $85.00 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veloxis Pharmaceuticals, INC. | $79.83 | 2021 | |
| Sanofi-Aventis U.S. LLC | $73.20 | 2024-2025 | |
| Cognoa, INC. | $66.96 | 2021-2022 | |
| Travere Therapeutics, INC. | $66.86 | 2022-2023 | |
| Seqirus USA INC | $47.83 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $44.93 | 2023-2024 | Flumist Quadrivalent |
| Lnhc, INC | $43.78 | 2025 | Zelsuvmi |
| Arbor Pharmaceuticals, INC. | $43.29 | 2019-2020 | |
| Radius Health, INC. | $35.00 | 2019 | |
| Dermira, INC. | $33.72 | 2020 | |
| Coloplast Corp | $27.79 | 2019 | |
| Galderma Laboratories, L.P. | $20.52 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $20.44 | 2021 | |
| Solventum Corporation | $18.92 | 2025 | 3m Espe Filtek Supreme Ultra Universal Restorative, Scotchbond Universal, Relyx Unicem Aplicap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmeet Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.